Company profile · free preview
First Tracks Biotherapeutics Inc
TRAX · NASDAQ · Healthcare · Updated 11/13/2026
Five-year financials
| Fiscal year |
|---|
| Revenue |
| Net income |
| Diluted EPS |
| Operating cash flow |
| Free cash flow |
| Cash |
| Total debt |
Financials are being prepared.
Want the story behind these numbers? Ask Osiris anything about First Tracks Biotherapeutics Inc's filings — free.
Create free accountFirst Tracks Biotherapeutics Inc return on capital (fiscal 2024)
ROIC
—
Return on capital
—
Return on equity
-40.9%
Return on assets
-37.0%
Gross margin
—
Operating margin
—
Net debt / EBITDA
0.69x
First Tracks Biotherapeutics Inc insider buying and selling
Recent open-market trades reported on Form 4. Context only — not a reason to buy or sell.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-02 | Ware J. Anthony | Sale | 39,265 | $44.78 |
SEC filings
- S-12026-10-26EDGAR
Ask anything about First Tracks Biotherapeutics Inc's filings
"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.
Start researching freeCompare TRAX head-to-head
More Healthcare companies
TScan Therapeutics, Inc. TCRXTempus AI, Inc. TEMTeva Pharmaceutical Industries Limited TEVATransMedics Group, Inc. TMDXThermo Fisher Scientific TMOTenon Medical, Inc. TNONTwist Bioscience TWST10x Genomics, Inc. TXGUnitedHealth Group UNHU.S. Physical Therapy USPHVera Therapeutics, Inc. VERAViking Therapeutics VKTX